<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02941848</url>
  </required_header>
  <id_info>
    <org_study_id>HM-ROZE-102</org_study_id>
    <nct_id>NCT02941848</nct_id>
  </id_info>
  <brief_title>Evaluate the Pharmacokinetics and Safety of HCP1306 and Co-administration of HGP0816, HGP1404 in Healthy Male Volunteers</brief_title>
  <official_title>A Randomized, Open-Label, Two-way Crossover, Single-Dose Study to Compare Pharmacokinetic Properties and Safety After Administration of HCP1306 Tablet and Co-administration of HGP0816 Tablet, HGP1404 Tablet in the Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanmi Pharmaceutical Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanmi Pharmaceutical Company Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate Pharmacokinetic Properties and Safety after
      administration of HCP1306 tablet and Co-administration of HGP0816 tablet, HGP1404 tablet in
      the healthy adults.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Randomized, Open-Label, Two-way Crossover, Single-Dose Study to Compare Pharmacokinetic
      Properties and Safety after administration of HCP1306 tablet and Co-administration of HGP0816
      tablet, HGP1404 tablet in the healthy adults
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUClast of Rosuvastatin</measure>
    <time_frame>Pre-dose, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of Rosuvastatin</measure>
    <time_frame>Pre-dose, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast of Free Ezetimibe</measure>
    <time_frame>Pre-dose, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of Free Ezetimibe</measure>
    <time_frame>Pre-dose, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUCinf of Rosuvastatin</measure>
    <time_frame>Pre-dose, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax of Rosuvastatin</measure>
    <time_frame>Pre-dose, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of Rosuvastatin</measure>
    <time_frame>Pre-dose, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F of Rosuvastatin</measure>
    <time_frame>Pre-dose, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd/F of Rosuvastatin</measure>
    <time_frame>Pre-dose, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRT of Rosuvastatin</measure>
    <time_frame>Pre-dose, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf of Free Ezetimibe</measure>
    <time_frame>Pre-dose, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of Free Ezetimibe</measure>
    <time_frame>Pre-dose, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2 of Free Ezetimibe</measure>
    <time_frame>Pre-dose, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F of Free Ezetimibe</measure>
    <time_frame>Pre-dose, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd/F of Free Ezetimibe</measure>
    <time_frame>Pre-dose, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRT of Free Ezetimibe</measure>
    <time_frame>Pre-dose, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Primary Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Group1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>C → A + B
A : HGP0816 B : HGP1404 C : HCP1306</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A + B → C
A : HGP0816 B : HGP1404 C : HCP1306</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HGP0816</intervention_name>
    <arm_group_label>Group1</arm_group_label>
    <arm_group_label>Group2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HGP1404</intervention_name>
    <arm_group_label>Group1</arm_group_label>
    <arm_group_label>Group2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HCP1306</intervention_name>
    <arm_group_label>Group1</arm_group_label>
    <arm_group_label>Group2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        [Inclusion criteria]

          1. Healthy adult of 19 to 50 of age at screening.

          2. 18.5 ≤ Body mass index (BMI) &lt; 25.

             ※ BMS (kg/m2)= body weight (kg)/[height (m)2]

          3. Body weight ≥ 55 kg for men and ≥ 50 kg for women.

          4. Individual considered by the responsible physician to be eligible as a subject based
             on the results of hematology test, blood chemistry test, immunoserology test,
             urinalysis, and electrocardiogram (ECG) as performed according to the characteristics
             of the drug (including those with not clinically significant (NCS) abnormalities).

          5. Women must have a negative serum β-human chorionic gonadotropin (β-hCG) pregnancy test
             at screening and a negative pre-dose urine β-hCG test at a time point defined in the
             protocol and must be applicable to one of the followings.

               -  Postmenopausal (no spontaneous menstruation for at least 2 years)

               -  Surgical sterilization (sterilized by hysterectomy, bilateral ovariectomy or
                  tubal ligation, or other methods)

               -  A male partner is sterilized prior to screening (documented azoospermia following
                  vasectomy) and this man is the subject's only partner.

               -  The subject must agree to use adequate methods of contraception continuously and
                  properly during the period of time from at least 14 days prior to the first dose
                  to at least 28 days after the last dose of the investigational product.

                    -  Adequate methods of contraception include abstinence and physical barrier
                       methods (e.g., condom, diaphragm, or cervical cap) and contraceptive devices
                       or pills containing hormones that may have drug-drug interactions with the
                       investigational product are not to be used during the study period, in
                       principle.

          6. Sexually active male subject with a female partner of childbearing potential must
             agree to avoid pregnancy (condom, etc.) during the study and to maintain adequate
             methods of contraception and not donate sperms during the study and for 28 days after
             the last dose of the investigational product (the methods of contraception are not
             necessary if the male subject or his female partner is sterile).

          7. After receiving and understanding sufficient explanations about the study, the
             individual must voluntarily decide to participate in the study and provide written
             informed consent to complying with study instructions.

        [Exclusion criteria]

          1. Evidence or history of clinically significant diseases in the hepatobiliary system,
             kidney, nervous system, psychiatric system, respiratory system, endocrine system
             (thyroid dysfunction, etc.), hemato-oncology, cardiovascular system, immune system, or
             musculoskeletal system (myopathy, etc.).

          2. History of gastrointestinal disorders (e.g., Crohn's disease, ulcerative colitis) or
             surgery (except for simple typhlotomy or hernia repair) that may affect the absorption
             of the investigational product.

          3. Hypersensitivity reactions to any of the components of the investigational product or
             its excipients or drugs of the same class.

          4. Hereditary disorders such as galactose intolerance, Lapp lactase deficiency, or
             glucose-galactose malabsorption.

          5. Vital signs measured in the sitting position after at least 5 minutes of rest as
             follows: systolic blood pressure (SBP) &gt; 150 mmHg or &lt; 90 mmHg or diastolic blood
             pressure (DBP) &gt; 100 mmHg or &lt; 50 mmHg.

          6. Screening clinical laboratory test results as follows:

               -  Blood total bilirubin level &gt; 1.5 x upper limit of normal (ULN)

               -  Blood aspartate aminotransferase (AST, also known as serum glutamic oxaloacetic
                  transaminase [SGOT]) or alanine aminotransferase (ALT, also known as serum
                  glutamate pyruvate transaminase [SGPT]) &gt; 1.25 x ULN

               -  Blood urea nitrogen (BUN) &gt; 25.0 mg/dL or creatinine &gt; 1.4 mg/dL

               -  Estimated glomerular filtration rate (eGFR) &lt; 60 mL/min/1.73m2 as calculated by
                  the Modification of Diet in Renal Disease (MDRD) equation

                  ※ eGFR (mL/min/1.73m2) = 175 x [serum creatinine (mg/dL)]-1.154 x [age
                  (years)]-0.203 (X 0.742, if female)

               -  Blood Creatinine Phosphokinase (CK) &gt; 2 x ULN

          7. History of significant drug abuse within 1 year of screening or positive urine drug
             test results.

          8. Administration of drugs within 30 days of the investigational product administration
             that are expected to or may affect the metabolism of the investigational product.

          9. Administration of the following drugs within the relevant period, except for local
             agents without significant systemic absorption and hormonal contraceptives.

               -  Ethical (ETC) drugs within 14 days of the first investigational product
                  administration

               -  Over-the-counter (OTC) drugs including health foods and vitamin preparations
                  within 7 days of the first investigational product administration

               -  Drugs administered via depot injection or other implantations (except for
                  contraceptives) within 30 days of the first investigational product
                  administration

         10. Significant alcohol dependency within 1 year of screening, continuous drinking within
             6 months of screening (&gt; 210 g/week), or unable to refrain from drinking during the
             study period starting from 2 days prior to the first investigational product
             administration.

         11. Continuous caffeine intake (e.g., coffee &gt; 5 cups/day, tea &gt; 1250 cc/day, cola &gt; 1250
             cc/day) or unable to refrain from caffeine intake during the study period starting
             from 2 days prior to the first investigational product administration.

         12. Continuous smoking (&gt; 10 cigarettes/day) or unable to refrain from smoking during the
             study period starting from 2 days prior to the first investigational product
             administration.

         13. Intake of grapefruits or foods containing grapefruits within 7 days prior to the first
             investigational product administration.

         14. Participation in another clinical trial (including a bioequivalence study) and
             administration of another investigational product within 60 days prior to the
             investigational product administration in this study (3 months for biologics; a
             prolonged period of time may be applied with half life taken into account).

         15. Whole blood donation within 60 days or apheresis donation within 30 days prior to the
             investigational product administration.

         16. Pregnant or lactating women.

         17. Subject considered by the investigator to be inappropriate for study participation due
             to other reasons.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Choon Ok Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yonsei University Health System, Severance Hospital</affiliation>
  </overall_official>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 11, 2016</study_first_submitted>
  <study_first_submitted_qc>October 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2016</study_first_posted>
  <last_update_submitted>October 19, 2016</last_update_submitted>
  <last_update_submitted_qc>October 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

